• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Creative Medical Technology Holdings Inc.

    12/8/21 5:00:35 PM ET
    $CELZ
    Finance: Consumer Services
    Finance
    Get the next $CELZ alert in real time by email
    SC 13G 1 l1cap_scd13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Creative Medical Technology Holdings, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    22529Y309
    (CUSIP Number)
     
    December 7, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     
     CUSIP No.  22529Y309   13G   Page 2 of 5 Pages

     

     

    1  NAME OF REPORTING PERSONS
       
      L1 Capital Global Opportunities Master Fund Ltd.
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands 
      5                  SOLE VOTING POWER
         
        327,458 shares of Common Stock(1)(2)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH   327,458 shares of Common Stock(1)(2)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
       327,458 shares of Common Stock(1)(2)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.1%(3)
    12 TYPE OF REPORTING PERSON
     

     

    FI

           

    (1) Represents 327,458 shares of Common Stock held by the reporting person. The number of shares reported to be beneficially owned: (i) gives effect to 85,458 shares of Common Stock issuable upon exercise of a Common Stock Purchase Warrant issued on August 11, 2021 (the “August 2021 Warrant”) and (ii) does not give effect to 242,000 shares of Common Stock issuable upon exercise of a Common Stock Purchase Warrant issued on December 7, 2021 (the “Public Warrant”).  Due to a 4.99%  beneficial ownership limitation in the Public Warrant, the reporting person has no beneficial ownership of the Common Stock issuable upon exercise of the Public Warrant. The August 2021 Warrant contains a 9.99% beneficial ownership limitation.

     

    (2) David Feldman and Joel Arber are both the directors of L1 Capital Global Opportunities Master Fund Ltd. As such they each individually have sole dispositive and voting power.

     

    (3) The reporting person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

     

     
     

     

     CUSIP No.  22529Y309   13G   Page 3 of 5 Pages

     

     

    Item 1. Security and Issuer.

     

      (a) Name of Issuer:

     

    Creative Medical Technology Holdings, Inc.

     

     

    (b)

     

    Address of Issuer:

     

    211 E Osborn Road

    Phoenix, AZ 85012

     

    Item 2. Identity and Background.

     

    (a)  Name of Person Filing:
       
      L1 Capital Global Opportunities Master Fund, Ltd.
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    161A Shedden Road, 1 Artillery Court

    PO Box 10085

    Grand Cayman, Cayman Islands KY1-1001

       
    (c) Citizenship or Place of Organization:
       
      Cayman Islands
       
    (d) Title of Class of Securities:
       
      Common Stock, $0.001 par value
       
    (e)  CUSIP Number:
       
       22529Y309  

     

    Item 3.

     

    Not applicable.

     

     
     

     

     CUSIP No.  22529Y309   13G   Page 4 of 5 Pages

     

     

    Item 4. Ownership.

     

      (a) The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

      (b) The percentage set forth on Row (11) of the cover page for the Reporting Person is based on 6,327,348 shares of Common Stock outstanding.

     

      (c) David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund Ltd. As such, L1 Capital Global Opportunities Master Fund Ltd,  Mr. Feldman and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) 327,458 shares of Common Stock. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such shares, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

     

      (d) The Reporting Person is a beneficial owner of 327,458 shares of Common Stock. The number of shares reported to be beneficially owned: (i) gives effect to 85,458 shares of Common Stock issuable upon exercise of a Common Stock Purchase Warrant issued on August 11, 2021 (the August 2021 Warrant”) and (ii) does not give effect to 242,000 shares of Common Stock issuable upon exercise of a Common Stock Purchase Warrant issued on December 7, 2021 (the “Public Warrant”).  Due to a 4.99%  beneficial ownership limitation in the Public Warrant, the reporting person has no beneficial ownership of the Common Stock issuable upon exercise of the Public Warrant. The August 2021 Warrant contains a 9.99% beneficial ownership limitation.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

     

     

     
     

     

     CUSIP No.  22529Y309   13G   Page 5 of 5 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:    L1 Capital Global Opportunities Master Fund Ltd.
         
    December 8, 2021 By: /s/ David Feldman
        David Feldman, Director

     

     

     

    Get the next $CELZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELZ

    DatePrice TargetRatingAnalyst
    2/25/2022$10.00Buy
    Roth Capital
    More analyst ratings

    $CELZ
    SEC Filings

    View All

    SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.

    DEF 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    10/30/25 6:11:46 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    8/8/25 4:45:55 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    5/9/25 4:45:24 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

    PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate

    10/29/25 9:00:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Issues Letter to Shareholders

    PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company's history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications. At the

    10/27/25 8:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

    PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel wi

    10/7/25 9:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Creative Medical Tech with a new price target

    Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00

    2/25/22 9:18:39 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Finger Michael H. sold $8,062 worth of shares (1,500 units at $5.38), decreasing direct ownership by 81% to 351 units (SEC Form 4)

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    2/20/25 7:23:52 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Warbington Timothy

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    6/29/23 5:37:18 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4: Warbington Timothy bought $9,862 worth of shares (25,000 units at $0.39), increasing direct ownership by 29% to 112,087 units

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    11/23/22 9:09:14 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Leadership Updates

    Live Leadership Updates

    View All

    Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

    PHOENIX, Ariz. , March 2, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing, and business development. He most recently served

    3/2/22 8:30:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/26/23 10:23:18 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Creative Medical Technology Holdings Inc.

    SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/1/23 9:49:02 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    2/14/22 3:30:56 PM ET
    $CELZ
    Finance: Consumer Services
    Finance